Monness, Crespi, Hardt Initiates Coverage on Incyte (INCY) with a Buy
INCY Hot Sheet
Rating Summary:9 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Monness, Crespi, Hardt initiates coverage on Incyte (Nasdaq: INCY) with a Buy rating.
To see all the upgrades/downgrades on shares of INCY, visit our Analyst Ratings page.
Incyte Corporation (Incyte) is a drug discovery and development company focused on developing small molecule drugs to treat serious unmet medical needs.
To see all the upgrades/downgrades on shares of INCY, visit our Analyst Ratings page.
Incyte Corporation (Incyte) is a drug discovery and development company focused on developing small molecule drugs to treat serious unmet medical needs.
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- Wunderlich Securities Starts Fastenal (FAST) at Buy
- Nomura Securities Maintains a 'Neutral' on Tiffany & Co. (TIF); Cutting Estimates and Price Target
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
